{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-087352","form_type":"8-K","ticker":null,"cik":"0001697532","company_name":"Applied Therapeutics, Inc.","filed_at":"2025-06-17T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.377191+00:00","generated_at":"2026-05-19T04:43:02.954062+00:00","sec_items":["5.02","7.01","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Applied Therapeutics reports mixed govorestat Phase 2/3 results; CMO departs, Bailey named","bullets":["INSPIRE trial primary endpoint 10MWRT not met (p=0.7287); stat sig correlation between sorbitol reduction and CMT-HI (p<0.001) and lower limb domain (p=0.038).","Key secondary endpoint CMT-HI showed stat sig improvement at 12 months; sorbitol reduction maintained through 24 months; MRIs suggest slowing of disease progression.","CMO Riccardo Perfetti departed June 15; Evan Bailey appointed CMO. Bailey gets $585k base salary, 300k RSUs vesting over 4 years.","Govorestat generally safe and well tolerated through 24 months; similar adverse event rates between active and placebo groups."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-087352","json":"https://secwatch.observer/filing/0000950170-25-087352.json","markdown":"https://secwatch.observer/filing/0000950170-25-087352.md","text":"https://secwatch.observer/filing/0000950170-25-087352.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1697532/000095017025087352/0000950170-25-087352-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1697532/000095017025087352/aplt-20250615.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-19T04:43:02.954062+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"21f42b08a1","claim":"Riccardo Perfetti departed as Chief Medical Officer at Applied Therapeutics, Inc..","evidence_excerpt":"Riccardo Perfetti, M.D., Ph.D., departed his role as Chief Medical Officer, effective as of June 15, 2025.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1697532/000095017025087352/0000950170-25-087352-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"departed"},{"label":"Role","value":"Chief Medical Officer"}],"fact_type":"executive_change"},{"claim_id":"bdf8e95f46","claim":"Evan P. Bailey was appointed as Chief Medical Officer at Applied Therapeutics, Inc..","evidence_excerpt":"Effective as of June 15, 2025, the Board appointed Evan P. Bailey, the Company’s Senior Vice President, Clinical Development, to succeed Dr. Perfetti as Chief Medical Officer.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1697532/000095017025087352/0000950170-25-087352-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Medical Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}